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GENETIC DISSECTION OF HUMAN BLOOD
PRESSURE VARIATION: COMMON PATHWAYS
FROM RARE PHENOTYPES
RICHARD P. LIFTON
Howard Hughes Medical Institute, Department of Genetics,
Yale University School ofMedicine, New Haven, Connecticut

H

I.

INTRODUCTION

eart disease and stroke are the number one and number three
leading causes of death in the United States, accounting for more
than a third of all deaths annually. Epidemiologic studies have established
a number of risk factors for these diseases, including hypertension, high
cholesterol, diabetes mellicus, and smoking. Prospective randomized trials
of blood pressure lowering, cholesterol reduction, and smoking cessation
have established the causal relationship of these risk factors to disease,
because modifying these parameters prevents adverse clinical outcomes,
including death.
In the case of cholesterol, initial therapeutic agents had modest
cholesterol-lowering effects chat reduced risk of heart attack but did not
reduce overall mortality. Understanding the cholesterol biosynthecic
pathway ultimately led to identification ofrate-limiting steps in the pathway
and development of highly potent cholesterol-lowering agents, the HMG
CoA reduccase inhibitors. These agents lower cholesterol far more than
their predecessors and markedly reduce both morbidity and overall·mortal
ity. These studies underscore the importance of identifying the right targets
in the right pathways in order to achieve optimal clinical results.
Hypertension is the most common disease of the industrialized world,
affecting one billion people world-wide and more than 70% of the elderly
population. Treatment of hypertension has clear benefit co reduce the
incidence of stroke and heart attack (Multiple Risk Factor Intervention
Trial Research Group, 1982; Medical Research Council Working Party,
71
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1985). Nonetheless, the blood pressure reduction achieved with current
single medications is relatively modest in most treated subjects; only a
small minority of hypertensive individuals achieve the goals of blood
pressure reduction, leaving considerable room for improvement in therapy.
Efforts to improve therapy, however, have been complicated by a lack of
understanding of the main pathways that determine long-term blood
pressure homeostasis and the key points in these pathways that would
represent the best therapeutic targets. This uncertainty arises from the
complex physiologic regulation of blood pressure, with inputs from the
brain, heart, adrenal, kidney, vasculature, and endocrine systems (Fig.
3.1). Consequently, the field has been plagued with many proposals as to
where primary abnormalities might lie with little substantiating data.
,-----·---------··---·-····--·--·
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Fig. 3.1. Model of blood pressure homeostasis. The wiring diagram of a computer
model of blood pressure homeostasis devised by Arthur Guyton. The model illustrates the
many organs and physiologic systems chat have inpur inco blood pressure homeostasis.
Reproduced with permission from the Annual Review ofPhysiology, Volume 34, copyright
1972 by Annual Reviews, www.annualreviews.org.
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II. GENETIC APPROACHES TO UNDERSTAND COMPLEX TRAITS

In the setting of such complex systems biology, geneti� approaches
have considerable merit. Most importantly, they can definitively settle
the question of causality that commonly plagues analysis of complex
systems.
There are multiple approaches one might rake to this problem. We
were initially inspired by genetic approaches in model organisms, in
which complex systems like development have been effectively dissected
by large-scale muragenic screens, looking for mutations char impart large
effects in order to identify the key genes and pathways that affect the trait
in question (Nusslein-Volhard and Wieschaus, 1980). This suggested a
search not for common alleles in the general population char might impart
incremental effects on the trait, bur for rare alleles with very large effects
that should define the important underlying pathways that control the
trait. While one cannot perform mutagenesis in humans, one can rake
advantage of the presence of the more than 12 billion copies of the human
genome in existence among the world's inhabitants. With a 3 billion base
pair genome and reasonable estimates of the mutation frequency, muta
tions altering virtually every base in the genome that are compatible with
survival exist somewhere on the planet, and they come to medical atten
tion. Owing to high rares of consanguinity in a number of cultures, even
rare recessive alleles can be found in the homozygous state.
These considerations motivated our efforts to systematically scour the
globe for extreme outliers with either extremely high or extremely low
blood pressure, followed by clinical investigation of the index case and
the extended kindred to identify distinct physiologic features and to
determine whether blood pressure or related endophenotypes show evi
dence of Mendelian segregation. Among such families, mapping studies
comparing the transmission of each chromosome segment to the inher
tance of altered blood pressure can pinpoint the location of the underlying
disease gene, and screening of genes in the linked interval can identify
underlying functional mutations. Importantly, the typical occurrence of
independent mutations among unrelated kindreds chat segregate with the
trait and which show specificity for the trait settle the issue of causality,
an important advantage. The demonstration of single gene mutations that
impart large effects on blood pressure have the capacity to identify key
rate-determining steps and pathways for the behavior of the overall system.
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These sites represent logical points at which therapeutic intervention
might have the greatest impact. Importantly, as for cholesterol homeosta
sis, intervention at these rate-determining steps may have the greatest
therapeutic impact in the general population, regardless of the presence
or absence of mutations in this pathway.
To date, we have used this approach to identify mutations in eight
genes that raise blood pressure and another eight genes in which mutation
lowers blood pressure. The most striking finding from these studies is
that these genes define a final common pathway that regulates renal salt
handling: Mutations that increase net renal salt reabsorption raise
blood pressure, and mutations that reduce salt reabsorption lower blood
pressure.

III.

RENAL SALT HOMEOSTASIS

In order to understand the relationship between salt and blood pres
sure, a basic knowledge of renal salt homeostasis is required. Every day
the kidneys of a normal adult filtei: 170 liters of plasma containing 1.5 kg
of salt. Consequently, on a typical Western 5-g salt diet, the kidneys must
reabsorb all but about 0.5% of the filtered load of salt to maintain homeo
stasis. The amount of water reabsorbed is precisely regulated to maintain
a serum sodium concentration very close to 140 mM. As a consequence,
increased salt reabsorption initially leads to higher plasma volume; con
versely, reduced salt reabsorption results in lower plasma volume.
The kidneys achieve salt homeostasis by a complex, integrated set of
exchangers, cotransporters, and channels that act in distinct nephron seg
ments (Fig. 3.2). Bulk reabsorption occurs proximally, with progressively
smaller fractions reabsorbed in each subsequent nephron segment. About
60% of the filtered sodium load of salt is reabsorbed by Na+/H+ exchange
in the proximal tubule, 30% by the action of a Na+-K+-2ci- cotrans
porter in the thick ascending limb of Henle, 7% by the action of a Na-Cl
cotransporter in the distal convoluted tubule, and the last 2% by the
action of the renal epithelial sodium channel (ENaC). Reabsorption of
Na+ via ENaC is electrogenic, providing the electrical driving force to
support either paracellular
reabsorption or K+ and H+ secretion.
The activity of this final channel, ENaC, is regulated by the renin
angiotensin system. The renin-angiotensin system is activated when the

o-
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Fig. 3.2. Elements contributing co renal sale homeostasis. A diagram of a nephron is
shown. Sodium filtered at the glomerulus is reabsorbed by four major mediators distributed
along the nephron as described in the text. Reabsorpcion of Na+ by che epithelial sodium
channel in the distal nephron is regulated by the activity of the renin-angiocensin system
via regulated production of the steroid hormone aldoscerone.

kidney senses reduced chloride delivery to the thick ascending limb of
Henle, resulting in secretion of the aspartyl protease renin by cells of the
juxtaglomerular appratus. Renin cleaves the circulating protein angioten
sinogen to angiotensin I, which is further cleaved by angiotensin convert
ing enzyme to the active peptide hormone angiotensin II. Angiotensin II
binds to specific receptors in the adrenal glomerulosa, which leads to
increased secretion of the steroid hormone aldosterone; aldosterone binds
to specific receptors in principal cells of the distal nephron, which ulti
mately leads to increased activity of the epithelial sodium channel.
The mutations our group has identified impart large effects on blood
pressure and/or related traits. In each case, families from around the world
have been identified and clinically characterized, and disease-causing
mutations have been identified. In nearly every case, biochemical and
clinical studies have established the specific mechanisms by which muta
tions increase or decrease renal salt reabsorption.
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MUTATIONS THAT RAISE BLOOD PRESSURE

A. Glucocorticoid-Remediable Aldosteronism (GRA)
GRA is an autosomal dominant trait featuring early onset of severe
hypertension (Sutherland et al., 1966). Physiologically, affected patients
have elevated levels of aldosterone despite suppression of renin levels.
Interestingly, aldosterone secretion in these patients is driven by adreno
corticotropic hormone (ACTH), the normal secretagogue for cortisol,
rather than angiotensin II. By investigation of families with GRA, we
demonstrated that this disease is caused by a gene duplication produced
by unequal crossing over between two genes involved in adrenal steroid
biosynthesis (Fig. 3.3; Lifton et al., 1992a,b). One of these genes encodes
aldosterone synthase, which is the rate-limiting step in aldosterone bio
synthesis in the adrenal glomerulosa and whose expression is normally
regulated by angiotensin II signaling. The other gene encodes steroid 11beta hydroxylase, which is employed in cortisol biosynthesis in adrenal
fasciculata and whose expression is regulated by adrenocorticotropic
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Fig. 3.3. The genetic basis of the hypertensive disease glucocorticoid-remediable aldo
steronism. Unequal crossing over between genes encoding aldosterone synthase and steroid
11-beta hydroxylase produces a chimeric gene duplication fusing 5' regulatory sequences
of 11-beta hydroxylase to coding sequences of aldosterone synthase. This leads to ectopic
expression of aldosterone synthase enzymatic activity in adrenal fasciculata under control
of ACTH.
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hormone (ACTH). These two genes have recently evolved from a common
ancestor; they are tightly linked on chromosome 8 in head-to-tail configu
ration and are 95% identical in DNA sequence. The chimeric gene dupli
cations that cause GRA fuse ACTH-responsive regulatory elements from
11-hydroxylase onto coding sequences that result in aldosterone synthase
enzymatic activity (Fig. 3.3). This results in expression of the rate-limiting
enzyme for aldosterone synthesis in the wrong tissue, the adrenal fascicu
lata, under control of the wrong hormone, ACTH. At the expense of
maintaining ACTH levels to support normal cortisol secretion, affected
subjects consequently have sustained aldosterone secretion.
This mutation results in hypertension by the following sequence:
Chronic aldosterone secretion leads to increased sodium reabsorption
via ENaC; water follows to maintain isotonicity of plasma, leading to
increased intravascular volume; this increases venous blood return to the
heart, and the cardiac stroke volume and cardiac output consequently
increases; by Ohm's law, this increase in cardiac output results in elevated
blood pressure. This elevation in blood pressure is sufficient to suppress
the activity of the renin angiotensin system; however, this fails to reduce
aldosterone secretion, since aldosterone secretion is now under control of
ACTH.

B. Mendelian Hypertension Exacerbated by Pregnancy
Aldosterone signals via the mineralocorticoid receptor, a member of
the nuclear hormone receptor family. By investigation of a unique family
with unexplained severe hypertension with suppressed renin and aldoste
rone secretion, we defined a new disease, demonstrated that it was trans
mitted as a simple autosomal dominant trait, and demonstrated that it is
caused by gain of function mutation in the mineralocorticoid receptor
(Geller et al., 2000). The disease-causing mutation is missense, and it lies
in the ligand binding domain of the mineralocorticoid receptor, substitut
ing leucine for a native serine in helix 5 (Fig. 3.4). Biochemical studies
in mammalian cells demonstrated partial activation of the mutant recep
tor in the absence of added steroid; more impressively, steroids such as
progesterone that lack a 21-hydroxyl group, which normally bind but fail
to activate the receptor, become very potent agonists for the mutant
receptor.
Molecular modeling followed by site-directed mutagenesis has shown
that the disease-causing mutation creates a key van der Waals interaction
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Fig. 3.4. Hypertension caused by mineralocorticoid receptor mutation. Molecular
model of aldosterone binding to the mineralocorticoid receptor is shown. The wild-type
receptor with Serine at position 810 is shown at right, and the mutant receptor with leucine
at position 810 is shown at left. L810 is capable of a new van der Waals interaction with
alanine 773 in helix 3, near the site where the 21-hydroxyl group of aldosterone interacts
with asparagine 770. This new interaction eliminates the requirement for the steroid 21hydroxyl group, resulting in receptor activation by progesterone and other steroids.

between helix 5 and helix 3 of the ligand binding domain. This new
interaction replaces the requirement for an interaction between the steroid
21-hydroxyl group and helix 3 of the receptor, allowing steroids lacking
chis moiety to become potent receptor agonises. These observations make
a clinical prediction: in normal pregnancy, progesterone levels rise 100fold; if progesterone is indeed an agonise for chis mutant receptor, women
harboring chis mutation should develop severe hypertension. This is
indeed the case. The five pregnancies among women harboring chis muta
tion have been accompanied by the development of extreme hyperten
sion, nece·ssicacing early delivery or termination of pregnancy. This is the
first demonstration of a molecular mechanism underlying this common
complication of pregnancy and demonstrate that it can arise from the
abnormal action of a normal hormone.

C. Liddle Syndrome
Downstream of the mineralocorticoid receptor lies its major target, the
epithelial sodium channel (ENaC). ENaC is composed of homologous
subunits encoded by three different genes, alpha, beta, and gamma. Muta
tions in ENaC subunits cause another Mendelian form of hypertension
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Fig. 3.5. Mutations in the epithelial sodium channel (ENaC) cause the hypertensive
disease Liddle syndrome. Mutations that delete or modify the PPPXY motif in the cyto
plasmic tail of the beta or gamma subunits of ENaC cause Liddle syndrome by impairing
the clearance of ENaC from the cell surface via endocytosis through clathrin-coated pits.

known as Liddle syndrome. This disease features early onset hypertension
transmitted as an autosomal dominant trait; affected patients have hyper
tension despite suppression of the renin-angiotensin system and reduced
levels of aldosterone. By investigation of families with this disease, we
have shown that Liddle syndrome is caused by mutations in the beta or
gamma ENaC subunits (Fig. 3.5; Shimkets et al., 1994, Hansson et al.,
1995); disease-causing mutations eliminate or alter single amino acids in
the cytoplasmic C-termini of these proteins. The target sequence for these
mutations is a PPPXY segment shared by these two subunits (Schild et
al., 1996). This shared sequence motif is required for the normal removal
of ENaC from the cell surface by endocytosis via clathrin-coated pits
(Shimkets et al., 1997). This sequence is recognized by 'WW domains of
Nedd-4, a ubiquitin ligase, implicating Nedd-4 in this clearance mecha
nism (Staub et al., 1996). These mutations thus result in a prolonged
half-life and increased levels of ENaC at the cell surface (Shimkets et al.,
1997). These channels are active and mediate increased sodium reabsorp
tion, thus feeding into the same final common pathway for hypertension
as patients with GRA and mineralocorticoid receptor mutations. These
findings establish that increased renal sodium reabsorption alone is suffi
cient to produce hypertension in humans, independent of mineralocorti
coid receptor action.
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It is tempting to speculate char the clearance mechanism for ENaC
discovered via Liddle syndrome is involved in the normal regulation of
ENaC activity by aldosterone. Recent data supports chis notion, linking
activity of an aldosterone-regulaced kinase, SGK, to regulation of Nedd4's activity on ENaC (Ichimura et al., 2005).

D. Genetic Screening
With the identification of the molecular basis of these autosomal domi
nant forms of hypertension, we have developed simple generic tests to
identify patients with these diseases. The purposes of such testing are
several, allowing determination of the prevalence of these diseases among
the hypertensive population, permitting studies of the impact of these
mutations on blood pressure and clinical outcomes in an unbiased fashion
by the study of extended kindreds, and permitting specific therapy tai
lored to the mutation among affected subjects. Over the last decade, we
have screened over 1000 samples sent by physicians from around the
world for evaluation of unexplained hypertension. Among these, we have
identified 42 new kindred� with GRA and 12 new kindreds with Liddle
syndrome, as well as over 200 additional affected subjects identified from
their relationship to an affected index case. The strongest predictors of a
positive test are onset of hypertension before the age of 20 and a first
degree relative with the same finding; among such subjects, 25% have
mutations in one of the above genes.
From these studies, we have also shown that these genes on average
impart a very large quantitative effect on blood pressure, approximating
30 mm Hg in the case of GRA. This marked effect on blood pressure has
important clinical consequences for affected patients: Patients with GRA
have a dramatic increase in the risk of intracranial hemorrhage before the
age of 45, most often due to rupture of aneurysms of the circle of Willis.
Prospective screening of affected subjects has identified asymptomatic
aneurysms char have resulted in premorbid surgical intervention. Identi
fication of these patients has also permitted therapeutic intervention with
agents tailored to the underlying primary abnormality.

V.

MUTATIONS THAT LOWER BLOOD PRESSURE

We are equally interested in mutations chat lower blood pressure,
because loss of function mutations chat reduce blood pressure may define
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therapeutic targets at which pharmacologic inhibitors would have benefi
cial blood-pressure-lowering effects. We have approached this problem
by investigating newborns with life-threatening hypotension.

A. Pseudohypoaldosteronism Type I (PHAI)
PHAI features severe hypotension in the neonatal period. There are
autosomal recessive, autosomal dominant and sporadic forms (Hanukoglu,
1991). Affected subjects have severe salt wasting despite marked ele
vations in renin and aldosterone. In addition to salt wasting, they also have
striking hyperkalemia and metabolic acidosis. These findings all point to
defective Na+ reabsorption in the distal nephron, since impaired Na+
reabsorption at this site would be expected to impair secretion of K+ and
protons.
We have shown that the recessive form of this disease is caused by
diverse loss of function mutations in subunits of ENaC, the same channel
in which gain of function mutations cause Liddle syndrome (Fig. 3.6;
Chang et al., 1996). We have also shown that the dominant form of

♦ Renin
♦
♦ Aldosterone

'

♦ MR Activation
Na M K•2CI
30%

Na+ 2%
K+, H+

♦ Salt Wasting
Fig. 3.6. Mutations in ENaC cause the hypotensive disease pseudohypoaldosteronism
type I. Loss of function mutations in ENaC result in massive sale wasting leading co activa
tion of the renin-angiotensin system. The loss of ENaC function prevents the increased
aldosterone level from increasing Na+ reabsorption. Due co the loss of electrogenic Na+
reabsorption via ENaC, K+ and H+ secretion are also impaired, resulting in hyperkalemia
and metabolic acidosis.
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PHAI is caused by heterozygous loss of function mutations in the min
eralocorticoid receptor (Geller et al., 1998). Most interestingly, while
neonates with either form of PHAI can be gravely ill in the neonatal
period, there are striking differences later in life. Patients with ENaC
mutations remain extremely dependent upon massive salt supplementa
tion and perpetual treatment to lower serum K+ levels. Mild intercurrent
illness can be life-threatening due to impaired dietary salt intake. In con
trast, patients with mineralocorticoid receptor mutations become asymp
tomatic, usually after age 2, and as adults are entirely asymptomatic, with
only a striking elevation in resting aldosterone levels as a biochemical
mark of their underlying defect (Geller et al., in preparation).
These findings have several important clinical implications. Most sig
nificantly, they require a reconsideration of the long-held view that ENaC
is wholly dependent upon aldosterone, and that on a typical 5-g salt diet,
with suppression of the renin-angiotensin system, ENaC activity is dis
pensable. The fact that patients missing ENaC require 20-30 g of salt per
day to maintain a semblance of normal intravascular volume indicates the
essential role of ENaC for normal.homeostasis. These observations under
score the possibility of developing improved antihypertensive agents that
target ENaC (see below).

B. Gitelman Syndrome
The recognition that gain or loss offunction of ENaC lead to increased
or reduced blood pressure prompted consideration of the phenotypes that
might result from altered function of other mediators of renal salt reab
sorption. These led to the consideration of Gitelman syndrome and
Banter syndrome, two diseases featuring abnormalities in salt, potassium,
pH, magnesium, and calcium homeostasis (Bettinelli et al., 1992). We
showed thar- Gitelman syndrome is caused by recessive loss of function
mutations in the thiazide-sensitive Na-Cl cotransporter of the renal distal
convoluted tubule (NCC) (Simon et al., 1996a). This results in primary
salt wasting, along with activation of the renin-angiotensin system,
leading to increased ENaC activity, which, in turn, leads to hypokalemia
and metabolic alkalosis (Fig. 3.7). In addition, these patients uniformly
have both hypomagnesemia due to renal Mg2+ loss and hypocalciuria.
These latter features are not readily explained from known physiology but
indicate an essential requirement for NCC activity in the normal homeo
stasis of Mg2+ and Ca2+.
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Fig. 3.7. Mutations in the Na-Cl cotransporter (NCC) cause Gitelman syndrome.
Loss of function mutations in NCC result in salt wasting and induction of the renin
angiotensin system. This leads to a compensatory increase in Na + reabsorption via ENaC,
resulting in only modest reduction in blood pressure; the increased lumen-negative poten
tial results in increased elecrrogenic drive for K+ and H+ secretion, leading to hypokalemia
and metabolic alkalosis.

We hypothesized that the relatively mild salt wasting seen in this disease
should reduce blood pressure. This was tested by clinical investigation of
200 members of an extended kindred segregating two identified NCC
mutations. By genotyping kindred members, we were able to compare
the blood pressures of family members harboring zero, one, or two mutant
copies of the gene. The results demonstrated an average 8-mmHg reduc
tion in systolic blood pressure among homozygous mutant subjects, with
no reduction in blood pressure of heterozygotes. This reduction was
highly significant but nonetheless was somewhat less than might have
been anticipated. This led us to consider whether affected subjects might
in some way be compensating for their inherited defect. One obvious
means to achieve this would be to simply eat more salt. This was tested
by measuring 24-hour urinary Na+ excretion, which in steady state is the
best indicator of dietary salt intake. Interestingly, both the heterozygous
and homozygous mutant subjects were found to consume markedly more
salt than their wild-type relatives, indicating dietary compensation for the
inherited renal defect (Cruz et al., 2001).
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These findings have several interesting implications. First, they reveal
the complexity of the relationship between salt intake and blood pressure.
Epidemiologic studies over the last half-century have examined this rela
tionship, but have struggled to provide generalizable conclusions (Taubes,
1998). Kindreds such as this one provide suggestions as to why this rela
tionship is so confounded. In this family, the individuals with the lowest
blood pressure are those that are eating the most, not the least, salt. The
recognition that primary renal salt wasting induces increased dietary salt
consumption reveals the difficulty in demonstrating a simple relationship
between salt intake and blood pressure. Second, these findings also make
the interesting point that dietary taste for salt, which might have been
considered a complex behavioral trait, can be determined by the activity
of a protein in the kidney.
C. Bartter Syndrome
The related disease Bartter syndrome features a typically far more severe
form of salt wasting that has high morbidity and mortality in the neonatal
period. Affected subjects are n0w recognized to have, in addition to
hypokalemia and metabolic alkalosis, mild to severe hypercalciuria, with
a substantial fraction developing nephrocalcinosis resulting in renal
failure. This disease proves to result from a failure of salt reabsorption in
the renal thick ascending limb of Henle (TAL) and define the pathway
by which salt traverses the TAL (Fig. 3.8). To date, loss offunction muta
tions in four genes have been identified that result in related phenotypes.
One of these, the Na-K-2Cl cotransporter encoded by NKCC2, mediates
the entry of salt from the lumen into the epithelium of this nephron
segment; homozygous loss of function mutations in this gene are one
cause of Bartter syndrome (Simon et al., 19966).
Potassium entering epithelial cells of the TAL via NKCC2 is recycled
back into the lumen by the K+ channel ROMK, and recessive loss of
function mutation in this channel results in a related phenotype (Simon
et al., 1996c). The explanation for this phenocopy is that fluid in the
TAL is high in Na and Cl but low in K. Consequently, without the
"recycling" of K+ entering the cell back into the lumen via ROMK (Fig.
3.8), there is not sufficient K+ in the lumen to permit normal extraction
of Na+ and Ct by NKCC2. Interestingly, these patients have severe salt
wasting, but their K+ loss is much less than seen among patients with
NKCC2 mutations. The reason for this is likely that ROMK is also used
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Fig. 3.8. Mutations that impair salt reabsorption in the thick ascending limb of Henle
(TAL) cause the hypotensive disease Barner syndrome. Mutations in genes that mediate
apical entry of Na-K-2Cl, the recycling of K+ back into the lumen, or exit of c1- across
the basolateral membrane in the TAL typically cause severe salt wasting and Barner
syndrome.

for K+ secretion in the distal nephron. This observation has interesting
therapeutic implications (see below).
NaCl entering the epithelial cell of the TAL must return to the blood
stream by traversing the basolateral membrane. Recessive loss of function
mutations in the c1- channel encoded by CLCNKB results in another
subset of patients with Bartter syndrome and identifies this channel as a
required component of this exit step (Simon et al., 1997). Interestingly,
this channel, when expressed alone in Xenopus oocytes, is inactive, sug
gesting the requirement for an accessory subunit. Recently, Birkenhager
and colleagues (2002) have identified such an accessory subunit of this
channel by idenification of mutations in the protein Barttin in another
group of Bartter patients.
Genotype-phenotype correlations have demonstrated that much of the
clinical variability seen among Bartter patients is explained by the differ
ent genes that are mutated to produce this phenotype. For example,
patients with mutations in CLCNKB or Barttin have more modest hyper
calciuria and less often have nephrocalcinosis, a feature that is nearly
always found among patients with mutations in NKCC2 and ROMK.
Patients with mutations in ROMK typically present in the neonatal
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period with paradoxical hyperkalemia and evolve over time to hypokale
mia that rarely requires K+ supplementation to the extent that other
Barner patients do.

VI.

NEW PATHWAYS FROM RECENT GENETIC STUDIES

A. A Complex Metabolic Syndrome Due to Mitochondrial Mutation
In the general population, hypertension is significantly associated with
a number of other traits, including insulin resistance, obesity, hyperlip
idemia, and hypomagmesemia. Together, these traits are often referred to
as the metabolic syndrome. The mechanisms underlying the clustering of
these traits has been unknown; however, the prevalence of this syndrome
is recognized to affect about 25 million Americans.
We ascertained and performed detailed clinical investigation of 142
blood relatives of a kindred with an unusually high prevalence of hyperten
sion, hypercholesterolemia, and hypomagnesemia (Fig. 3.9; Wilson et al.,
2004). We showed that each of these traits is strongly linked to the mater
nal lineage in this kindred; for example, all 32 kindred members with
clinically defined hypomagnesemia were on the same maternal lineage, a
finding extremely unlikely to occur by chance (p = 10-9). In addition, the
fraction of offspring of affected mothers who had hypomagnesemia signifi
cantly exceeded the number expected under autosomal dominant models
of transmission. Elevated blood pressure and elevated LDL and VLDL
cholesterol followed were similarly linked to the maternal lineage.
Since mitochondria are virtually exclusively maternally transmitted in
thousands of copies, these findings strongly implicate a mutation in the
16-kb miwchondrial genome as the cause of this syndrome. The mito
chondrial genome sequence revealed a novel mutation in the base imme
diately 5' to the anticodon of the mitochondrial isoleucine tRNA. The
normal uridine at this position is perhaps the most conserved base in all
of biology, owing to the essential role of its amino group in stabilizing
the anticodon loop, permitting presentation of the anticodon to the
codon of the cognate mRNA. Uridine is found at this position in every
ile tRNA from archaebacteria to humans and is also conserved in virtually
all other tRNAs, with notable exceptions of some initiator methionine
tRNAs in eukaryotes. This mutation is homoplasmic among all members
of the maternal lineage, regardless of phenotype.
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VI
Fig. 3.9. Kindred with mitochondrial hypomagnesemia, hypertension, and hypercho
lesterolemia. Kindred members with hypomagnesemia, hypertension, and hypercholester
olemia are denoted by filled symbols, the letter H and the letter C, respectively. Each of
these traits shows a marked increase on the maternal lineage, with strong support for
mitochondrial transmission.

Several aspects of these findings are of interest. First, they implicate
altered mitochondrial function in the pathogenesis of three new traits:
hypomagnesemia, elevated blood pressure, and elevated cholesterol. This
adds to the remarkably diverse list of traits that can result from mitochon
drial mutation (Wallace, 1999). Second, the clustering of these pheno
types is noteworthy: While virtually all of the clustering occurs on the
maternal lineage, within the maternal lineage the distribution of these
traits is nearly stochastic; this suggests that these traits are independent,
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pleiotropic consequences of the same mitochondrial mutation. This
observation underscores the complex patterns of clustering that can result
from the combined effects of pleiotropy and incomplete penetrance.
Finally, these findings raise the question of whether the loss of mitochon
drial function that is believed to accompany aging (Petersen et al., 2003)
may commonly contribute to the development of these traits. Interest
ingly, other components of the metabolic syndrome, such as insulin
resistance, have previously been linked to altered mitochondrial function,
thereby raising the possibility that the clustered abnormalities of the
metabolic syndrome might commonly be attributed to impaired mito
chondrial function.

B. Pseudohypoaldosteronism Type II-A Disease of
Disrupted Integration ofElectrolyte Flux
There are hundreds of ion channels, exchangers, contransporters,
and paracellular flux pathways distributed along the nephron. A major
question for the biology of this complex system is how the activities
of these diverse flux mediators are coordinated to achieve coherent
responses to physiologic perturbation. One might hope that genetic
approaches would identify mutations in key components of these regu
latory networks that disrupt the normal integration of these diverse
functions.
Pseudohypoaldosteronism type II (PHAII) appears to define just such
a higher-order regulator of function. PHAII features hypertension with
hyperkalemia and metabolic acidosis despite otherwise normal renal func
tion; it is transmitted as an autosomal dominant trait (Gordon et al.,
1995). Interestingly, the hypertension and hyperkalemia can be corrected
by low doses of thiazide diuretics or the removal of chloride from the
diet.
We have identified mutations in two novel serine threonine kinases,
Wnkl and Wnk4, as causes of PHAII (Wilson et al., 2001). Mutations
in Wnkl are large deletions in the first intron that increase expression of
Wnkl mRNA. Mutations in Wnk4 are missense and cluster within a
10-amino-acid acidic segment distal to the kinase domain. The expression
of these kinases in the kidney is confined to the distal convoluted tubule
and collecting duct of the nephron. Outside the kidney, these kinases are
expressed in diverse
transporting epithelia, including pancreatic ducts,
hepatic bile ducts, colonic crypts, and sweat ducts.

o-
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The clinical phenotypes and localization of these kinases suggest that
they are involved in the regulation of electrolyte flux. By expression
studies in Xenopus oocytes and mammalian cells, we have shown that this
is the case. Wnk4 regulates the activity of at least three transport pathways
in the distal nephron: the thiazide-sensitive NaCl cotransporter NCC
(Wilson et al., 2004; Yang et al., 2003), the K+ channel ROMK (Kahle
et al., 2003), and the paracellular flux pathway for c1- in the distal
nephron (Fig. 3.10; Yamauchi et al., 2004; Kahle et al., 2004). Wild-type
Wnk4 is a potent inhibitor of both NCC and ROMK; however, there
are important differences in the mechanism of inhibition. First, Wnk4's
inhibition of NCC is dependent upon its active kinase domain, whereas
inhibition of ROMK is kinase-independent. Second, while inhibition of
both is achieved by their reduced expression at the cell surface, inhibition
of ROMK is dependent upon endocytosis via clathrin-coated pits, whereas
inhibition of NCC is not. Most significantly, PHAII mutant Wnk4 has
opposite effects on these two targets, eliminating inhibition of NCC while
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Fig. 3.10. Wnk4 regulates the balance between c1- reabsorption and K+ secretion.
Wnk4 inhibits the activity of the NaCl corransporter in the distal convoluted tubule (OCT)
and the K+ channel ROMK in intercalated cells of the collecting duct. Mutations in WNK4
in patients with pseudohypoaldosteronism type II (PHAII) alleviate inhibition of NCC,
augment inhibition of ROMK, and increase paracellular Ct permeability. This results in
a net increase in NaCl reabsorption and reduced K+ secretion.
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increasing inhibition of ROMK. In addition, Wnk4 has effects on the
paracellular flux pathway. When expressed under control of doxycycline
in MDCK monolayers, expression of wild-type Wnk4 induces a selective
increase in the absolute paracellular permeability for Ct. PHAII-mutant
Wnk4 imparts a much larger effect to increase paracellular c1permeability.
These effects indicate that Wnk4 has properties of a molecular switch,
which enable it to have independent and divergent effects on highly
diverse flux pathways. PHAII-mutant Wnk4 is inferred to increase renal
NaCl reabsorption by increasing the activity of NCC and by increasing
permeability of the paracellular pathway for Ci-, allowing increased reab
sorption of Na+ with c1- in the distal nephron and concomitantly decreas
ing the electrical driving force to support K+ secretion. In parallel,
PHAII-mutant Wnk4 also inhibits K+ secretion directly, by inducing
clearance of ROMK from the cell surface. These effects of mutant Wnk4
can therefore explain the physiology observed in patients with PHAII.
These observations suggest that Wnk4's actions can explain a classic
paradox in renal physiology: Aldosterone is secreted in response to hypo
volemia via angiotensin II and also by direct effects of elevated K+ levels.
This raises the question of how the nephron is able to appropriately dis
tinguish these distinct stimuli, responding by maximally increasing NaCl
reabsorption in the former state while maximizing K+ secretion in the
latter condition. Wnk4 seems ideally poised to play a role in this decision.
We presume that the mutations that define PHAII mimic a normal
mechanism which sets the Wnk4 switch to promote NaCl reabsorption
while inhibiting K+ secretion. While further work will be required to
establish the upstream regulators of Wnk4, it is tempting to speculate
that angiotensin II might play a role, since this hormone is a distinguish
ing mark of hypovolemia versus hyperkalemia.

VIL

IMPLICATIONS

A. Pathophysiology ofHypertension
These studies have unequivocally established a causal relationship
between alteration of net renal salt reabsorption and altered blood pres
sure in humans; mutations that increase salt balance raise blood pressure
and mutations that reduce salt balance lower blood pressure (Fig. 3.11).
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The mechanisms of this effect can readily be explained via an initial
increase in plasma volume and cardiac output; over time, this hemody
namic pattern is modified to one of high systemic vascular resistance by
the local regulation .of.vascular beds to match perfusion to metabolic
demand (Guyton, 1991). Significantly, while there are diverse effects on
+

2+

K , Ca , and Mg

2+

homeostasis, in these diseases the vector for NaCl

consistently predicts the resulting effect on blood pressure.
These observations raise the question of whether other forms of hyper
tension also arise via increased renal salt reabsorption. The answer is
unequivocally yes, because virtually all of the acquired forms of hyper
tension arise via this mechanism. Aldosterone-producing adenoma is one
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obvious example, in which constitutive aldosterone secretion leads to
increased ENaC activity. Another is renal artery stenosis, in which
decreased perfusion of one kidney results in reduced
delivery to the
macula densa and increased secretion of renin. This activation of the
renin-angiotensin system ultimately feeds into the same final common
pathway of increased renal salt reabsorption. Similarly, the excess cate
chols in pheochromocytoma increase proximal renal tubular salt reabsorp
tion and also decrease renal blood flow. Finally, consumption of large
amounts of natural licorice produces hypertension by inhibition of an
enzyme, I I-beta hydroxysteroid dehydrogenase, which converts cortisol
to cortisone in principal cells of the collecting duct. Cortisol is a potent
agonist of the mineralocorticoid receptor and in the absence of its metab
olism to cortisone induces hypertension by activation of this receptor.
Finally, the impaired salt clearance seen in end-stage renal disease likely
accounts for the prevalence of hypertension among patients on dialysis;
this fraction approaches 100% in the United States. At present, one can
make the case that all of the known causes of hypertension act by increas
ing net salt balance, either by altering renal salt handling directly or as a
secondary effect resulting either from impaired blood flow to the kidney
or from impaired glomerular filtration.
Given that the genetic and acquired forms of hypertension act via
altered renal salt handling, it is tempting to speculate that the common
forms of hypertension will also arise by this mechanism with either a
direct effect on renal salt handling or an indirect one via reduced glo
merular filtration due to primary glomerular or renal vascular effects.
Large population studies are underway that will address whether rare or
common variants in genes in these pathways play a role in common forms
of hypertension. Regardless of the answer to this latter question, however,
the recognidon that blood pressure can be modulated from very low to
very high levels by alteration of renal salt balance has important implica
tions for the treatment of hypertension.

o-

B. Therapeutic Implications
1. Tailored Therapy for Rare Diseases. For the rare Mendelian hyperten
sive diseases discussed above, knowledge of their pathogenesis provides
the opportunity to direct therapy to the primary underlying abnormal
ity rather than an empiric approach. This is of clinical importance
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because without diagnosis, these patients are frequently thought to have
refractory hypertension. For example, in the case of GRA, patients can
be specifically treated with physiologic doses of glucocorticoids, which
suppresses secretion of ACTH and shuts down expression of the disease
causing chimeric gene. Other treatments that counter the effects of
aldosterone excess, such as mineralocorticoid antagonists or inhibitors
of ENaC, can also be effective. Similarly, patients with PHAII are
exquisitely sensitive to thiazide diuretics, which reduce activity of the
NaCl cotransporter whose activity is elevated in this disease. The value
of specific therapy among these patients underscores the importance of
diagnosing these diseases.

2. Hypertension in ESRD. As noted above, hypertension has a prevalence

that approaches 100% among the more than 300,000 patients in the
United States on dialysis for end-stage renal disease. This high prevalence
is very likely attributable to inadequate removal of salt and water on
dialysis, a consequence of efforts to reduce the number and time of dialysis
sessions. Recent studies that employ more frequent or longer dialysis
permit more net salt and water removal; these substantiate a dramatic
reduction in the prevalence of hypertension (Chan et al., 2002) and
strongly motivate modification of dialysis practice.

3. Treatment ofEssential Hypertension. These genetic studies reveal varia

tion in renal salt handling as a key site for long-term regulation of blood
pressure in humans. Most significantly, mutations in this process impart
very large effects on the trait, demonstrating the ability of this system to
modulate blood pressure from extremely low to extremely high values.
These observations implicate renal salt handling as a key target for thera
peutic intervention in the treatment of hypertension. This suggests that
drugs that target this pathway might be superior to agents that act on other
pathways. Recent randomized controlled trials support this notion. For
example, the 33,000-patient ALLHAT trial found that chlorthalidone, an
inhibitor of the NaCl cotransporter, was as good as or better than other
agents for all major clinical outcomes (ALLHAT Officers et al., 2002).
Similarly, the Life study, a large randomized controlled trial of the angio
tensin II receptor blocker losartan versus a beta blocker, showed superior
ity of losartan in prevention of stroke and overall morbid outcomes
(Dahlof et al., 2002). These findings strongly support the primary
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importance of reducing salt balance in the treatment of hypertension,
which is now reflected in national guidelines (Chobanian et al., 2003).
Nonetheless, it is apparent that treatment with existing single agents is
insufficient to achieve adequate blood pressure lowering in many patients.
One explanation for this is the interference of counter-regulatory mecha
nisms, like the increased dietaty salt intake documented among patients
genetically deficient for the NaCl cotransporter NCC, the target of thia
zide diuretics (Cruz et al., 2001). These observations suggest that initial
therapy with inhibitors of the NaCl cotransporter plus an ACE inhibitor
or All antagonist should achieve synergistic effects; this has been substan
tiated by clinical study. These observations argue that the long-standing
practice of starting therapy with a single agent is flawed, and they suggest
more rational approaches that start with synergistic combination thera
pies; recent national consensus recommendations reflect such a change in
approach (Chobanian et al., 2003).

C. New (and Old) Therapeutic Targets
These findings also have implications for new therapeutic development
for the treatment of hypertension applicable to the general population.
The most attractive targets are those that are pharmacologically tractable
and that induce the largest blood-pressure-lowering effects with the fewest
side effects. The phenotype resulting from loss of a gene product is a
strong predictor of both the efficacious and adverse effects of a pharma
cologic inhibitor of the gene product. The finding that loss of function
mutations in a number of ion channels and cotransporters result in
marked salt wasting and reduced blood pressure indicates that these chan
nels are poised at key points in integrated physiology and moreover are
not of redundant function; these genetic findings suggest that pharmaco
logic antagonists of these same channels and transporters would have
potent antihypertensive diuretic effects. New targets that are predicted to
have large effects on salt balance and blood pressure include the potassium
channel ROMK, the chloride channel CLCNKB, and potentially the
WNK kinases. Importantly, the paucity of clinical phenotypes in other
organs among patients lacking these transporters and channels suggests
that specific antagonists would not have limiting adverse effects in other
organs.
There are specific features of these targets that might give their antago
nists particular utility. For example, limiting side effects of treatment with
existing antagonists of the Na-K 2
-Cl cotransporter are the development
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of marked hypokalemia and deafness at higher doses. The potassium
channel ROMK is used for K+ recycling in the TAL and for K+ secretion
in the collecting duct. As a result, individuals deficient for ROMK have
massive Na+ depletion but only mild potassium wasting; their hearing is
also normal. These findings suggest that ROMK antagonists would have
potent diuretic effects like furosemide without the hypokalemic or loss of
hearing side effects. These might be superior agents for treatment of
hypertension as well as congestive heart failure.
Finally, some channels previously thought to be poor targets have been
resurrected by this work. Existing ENaC antagonists such as amiloride
are typically poor antihypertensive agents, which contributed to the false
impression that this channel normally contributes little to salt balance.
The massive salt wasting seen in patients who are deficient in ENaC
reveals that this channel is absolutely essential for normal salt homeostasis.
The limited efficacy of amiloride is attributable to the action of this drug
as a competitive antagonist for Na\ on a typical high salt diet, amiloride
cannot effectively compete with Na+ to achieve channel antagonism.
These considerations strongly suggest high efficacy of a potent ENaC
antagonist; in this case the resulting volume depletion could not be com
pensated by activation of the renin-angiotensin system, since EN aC is
itself the means by which this compensation is achieved. Due to its role
as the final arbiter of net Na+ reabsorption, ENaC could be the ideal
target; nonetheless, it is presently unknown whether hyperkalemia or
metabolic acidosis would be limiting adverse effects at higher levels of
channel inhibition.
D. Evolutionary Considerations
Given the strong evidence of the role of salt in the pathogenesis of
hypertension, the role of salt in the evolutionary history of humans is
worth considering. Sub-Saharan Africa is one of the most notoriously
salt-poor environments on earth. It is consequently highly likely that
genes that promoted avid salt retention were highly adaptive and strongly
selected in mankind's ancestral environment. After the diaspora of humans
to salt-rich environments, however, one can anticipate that those same_
alleles that were once adaptive lost their selective advantage and might
indeed have become deleterious due to their promotion of hypertension
and its morbid consequences. If this is correct, one might expect to see
ethnic variation in the prevalence of hypertension, with those whose
ancestors left Africa 100,000 years ago having a lower incidence of
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hypertension than those who only recently have been exposed to a high
salt diet. These considerations may help explain the markedly higher
prevalence of hypertension among African Americans and other recent
descendents of native African populations.
One prediction of this proposal is that alleles that promote salt reten
tion in the African population should be selected against and be reduced
in frequency in populations that long ago left Africa. For example, vari
ants in the angiotensinogen gene have been implicated as having modest
but significant effects on blood pressure (Jeunemaitre et al., 1992).
Intriguingly, the angiotensinogen allele conferring higher blood pressure
has a frequency near 100% in native African populations (Lifton et al.,
1993) but has been reduced to only 35% in Caucasian and Japanese
populations.

E. Understanding the Working of Integrated Systems
An important aspect of these genetic studies is their ability to provide
new insights into the integrated systems biology of blood pressure and
renal salt homeostasis. For example, the NaCl cotransporter of the DCT
normally mediates reabsorption of� 7% of the filtered salt load, whereas
the Na+ channel ENaC is responsible for only 1-2%. It is nonetheless
impossible to predict the impact of the loss of either of these due to the
unknown ability of other nephron segments to compensate for the loss
of one of these systems. Thus it is revealing that patients missing the
NaCl cotransporter have only about 8-mmHg reduction in blood pres
sure while patients deficient in ENaC require lifelong massive salt sup
plementation; we infer that the loss of NCC can be compensated by
increased activity of ENaC and/or other pathways, whereas loss of
ENaC activity cannot be reasonably compensated. This underscores
the role of ENaC as a key regulated step in the overall salt-retaining
pathway.
Second, these studies have identified the Wnk kinases as a previously
unknown regulatory system that has divergent effects on multiple com
ponents of the salt retaining and K+ secreting pathway. Prior to the
identification of the role of Wnk kinases in the regulation of ion flux,
it was commonly held that the integration of function of diverse flux
pathways was achieved indirectly, en passant, as a consequence of the
combined effects of changing electrochemical driving forces, hemody
namics, and tubular flow. Perhaps not surprisingly, the kidney has evolved
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additional mechanisms to achieve more direct control over the integrated
function of these pathways. In addition to being of interest from a systems
biology perspective, the Wnk kinase pathway represents a potentially
interesting new target for therapeutic intervention.
Finally, these studies also provide further insight into integrative physi
ology by identifying secondary effects of mutations in these salt-handling
pathways. For example, the marked effects of loss of function Na-Cl
cotransporter mutations in producing renal Mg2+ loss and Ca2+ retention
reveals unanticipated interrelationships between handling of salt in the
DCT and these divalent cations that would not have been predicted from
known physiology. The mechanisms linking genorype to phenotype in
this case are not presently understood, but indicate a deeper relationship
between homeostasis of salt and divalent cations than previously
appreciated.
VIII.

CONCLUSIONS

Genetic studies of humans with blood pressures at the extremes of the
distribution have established that primary alteration of net renal salt
reabsorption alters blood pressure in humans. The finding that the same
pathway is involved in many different diseases that feature altered blood
pressure suggests that altered renal salt handling likely underlies all forms
of hypertension. These findings have implications for the improved selec
tion and combination of medications to lower blood pressure. In addi
tion, new potential therapeutic targets have been identified at which
antagonists are likely to have improved efficacy and reduced adverse
effects compared with current therapies. These findings promise to
improve the treatment of hypertension and reduce its morbid outcomes.
Finally, the utility of investigating humans with extreme blood pressure
phenotypes to define the fundamental pathways that regulate this trait
serves as a model for similar approaches to other common complex traits
in humans.
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